• Explore /
  • Poster
  • / Myeloid-derived suppressor cell quantity prior to treatment with ipilimumab at 10mg/kg to predict for overall survival in patients with metastatic melanoma.

Myeloid-derived suppressor cell quantity prior to treatment with ipilimumab at 10mg/kg to predict for overall survival in patients with metastatic melanoma.

Abstract Poster

Authors

Shigehisa Kitano

Shigehisa Kitano

Memorial Sloan-Kettering Cancer Center, New York, NY

Shigehisa Kitano , Michael Andrew Postow , Czrina Cortez , Teresa Rasalan , Humilidad F. Gallardo , Katherine Panageas , Jianda Yuan , Jedd D. Wolchok , Alexander M. Lesokhin

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Therapeutics - Clinical Pharmacology and Immunotherapy

Track

Developmental Therapeutics

Sub Track

Immunotherapy and Biologic Therapy

Citation

J Clin Oncol 30, 2012 (suppl; abstr 2518)

DOI

10.1200/jco.2012.30.15_suppl.2518

Abstract #

2518

Poster Bd #

6

Abstract Disclosures

Similar Posters

First Author: Khashayar Esfahani

First Author: Jeffrey S. Weber

First Author: Jeffrey S. Weber

Poster

2023 ASCO Annual Meeting

<span>Melanomas lacking HLA class I expression and response to checkpoint inhibitor.</span>

Melanomas lacking HLA class I expression and response to checkpoint inhibitor.

First Author: Paul B. Chapman